<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254020</url>
  </required_header>
  <id_info>
    <org_study_id>380-2004</org_study_id>
    <nct_id>NCT00254020</nct_id>
  </id_info>
  <brief_title>The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression</brief_title>
  <official_title>The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is a common and often serious problem occurring in stroke patients. Inflammatory&#xD;
      hormones, known as cytokines, are stimulated by an activated immune system and sometimes&#xD;
      become active following a stroke. They may be responsible for altering levels of key&#xD;
      neurotransmitters and their metabolites in the blood and brain of stroke patients. The&#xD;
      investigators' objective is to examine whether increased cytokine activity following a stroke&#xD;
      may be the cause of an increased presence or severity of depression or cognitive impairment&#xD;
      among stroke patients, as a result of tryptophan depletion and/or kynurenine activation. They&#xD;
      are recruiting patients within one month of their strokes and measuring levels of key markers&#xD;
      in their blood. Patients are assessed for the presence of depressive and/or cognitive&#xD;
      symptoms and treated with an antidepressant if needed. The investigators expect to show that&#xD;
      cytokine activation is related to depression and/or cognitive impairment among stroke&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Centre for Epidemiological Studies-Depression Scale (CES-D)</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini Mental State Examination (MMSE)</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NINCDS-CSN Vascular Cognitive Impairment Battery</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Stroke Scale</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">138</enrollment>
  <condition>Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Patients who are found to have major depression will be referred to a psychologist</description>
    <other_name>Celexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Gender: male or female&#xD;
&#xD;
          -  Language: speaks and understands English&#xD;
&#xD;
          -  Clinical diagnosis of stroke according to World Health Organization MONICA Project and&#xD;
             recent (&lt; 3 months) cerebral infarctions&#xD;
&#xD;
          -  Written, informed consent&#xD;
&#xD;
          -  Depressed group only: diagnosis of a major depressive episode according to the&#xD;
             depression module of the Structured Clinical Interview for the DSM-IV (SCID-IV)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subarachnoid hemorrhage&#xD;
&#xD;
          -  Intracranial hemorrhage&#xD;
&#xD;
          -  Significant acute medical illness including: drug overdose, severely disturbed liver,&#xD;
             kidney or lung function, anemia, hypothyroidism, or uncontrolled diabetes&#xD;
&#xD;
          -  Significant acute neurologic illness including: impaired consciousness, Parkinson's&#xD;
             disease, Huntington's chorea, progressive supranuclear paralysis, brain tumor,&#xD;
             subdural hematoma, multiple sclerosis, hydrocephalus, Binswanger's disease, or severe&#xD;
             aphasia&#xD;
&#xD;
          -  Presence of a premorbid Axis I psychiatric diagnosis (eg. schizophrenia, bipolar&#xD;
             disorder)&#xD;
&#xD;
          -  Depressed group only: contraindications to receiving treatment with citalopram&#xD;
             (including previous nonresponse) or serious risk of suicide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krista L Lanctot, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>York Central Hospital</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 4Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Rehabilitation Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2M 2G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Rehabilitation Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baycrest</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Bensimon K, Herrmann N, Swardfager W, Yi H, Black SE, Gao FQ, Snaiderman A, Lanct√¥t KL. Kynurenine and depressive symptoms in a poststroke population. Neuropsychiatr Dis Treat. 2014 Sep 22;10:1827-35. doi: 10.2147/NDT.S65740. eCollection 2014.</citation>
    <PMID>25285006</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>November 10, 2005</study_first_submitted>
  <study_first_submitted_qc>November 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>depression</keyword>
  <keyword>cytokines</keyword>
  <keyword>serotonin</keyword>
  <keyword>citalopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

